Revenue Recognition (Details) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021 USD ($)	Dec. 31, 2023 USD ($) item $ / shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($) $ / shares	Aug. 31, 2019 USD ($)	Jun. 30, 2019 USD ($)
Revenue recognized		$ 19,500
Deferred revenue, Long-term		19,128	$ 20,001
Other assets		15,403	18,330
Deferred revenue		35,740	30,778	$ 28,722
Deferred revenue, current portion		16,612	10,777
Total revenues		1,082,571	820,222	625,486
Deferred revenue, long-term portion		19,128	20,001
Revenue recognized during the period that was included in deferred revenues at the beginning of the period		$ 10,564	8,782
Product
Approximate percentage of revenue collected within 9 months		90.00%
Billing collection period (in months)		9 months
Cost of revenues		$ 588,564	453,632	315,195
Total revenues		1,068,522	797,307	580,080
Tests delivered in prior periods that were fully collected
Increased (decreased) revenues		5,300	19,500	12,500
(Increased) decreased net loss		$ 5,300	$ 19,500	$ 12,500
(Increased) decreased net loss per share | $ / shares		$ 0.05	$ 0.20	$ 0.14
Amounts not refunded to insurance carriers
Increased (decreased) revenues		$ 13,100	$ 5,800	$ 5,700
(Increased) decreased net loss		$ 13,100	$ 5,800	$ 5,700
(Increased) decreased net loss per share | $ / shares		$ 0.11	$ 0.06	$ 0.06
Licensing and other
Cost of revenues		$ 1,267	$ 2,624	$ 3,223
Total revenues		14,049	22,915	45,406
Genetic testing services
Revenue recognized		18,300
Deferred revenue, current portion		13,700
Revenue recognized during the period that was included in deferred revenues at the beginning of the period		9,300
Qiagen | Other licensing and other revenue
Refunds of revenues previously deferred	$ 10,000
Deferred revenue	$ 28,600
BGI Genomics
Revenue recognized		$ 44,000
Agreement term		10 years
Revenue, remaining performance obligation		$ 6,000
Deferred revenue, Long-term		17,600
Transaction price		50,000
Deferred revenue		18,800
Deferred revenue, current portion		1,200
Prepaid royalties		20,000
Deferred revenue, long-term portion		17,600
BGI Genomics | License and related development services
Revenue recognized		$ 100	8,000	600
Number of performance obligations | item		2
Revenue, remaining performance obligation		$ 24,000
BGI Genomics | Sequencing services
Other assets		4,900				$ 6,000
BGI Genomics | Sequencing products
Other assets						4,000
Prepaid expenses and other current assets		3,100
Equipment and services received		5,100
BGI Genomics | Sequencing products and services
Other assets		1,800				$ 10,000
BGI Genomics | Oncology assay interpretation services
Revenue recognized		1,500	0	0
Revenue, remaining performance obligation		20,000
Deferred revenue		1,200
Foundation Medicine ("FMI")
Revenue recognized		$ 24,300
Agreement term		5 years
Automatic renewals, successive period thereafter		1 year
Revenue, remaining performance obligation		$ 7,700
Deferred revenue, Long-term		1,500
Transaction price					$ 32,000
Deferred revenue		3,200
Deferred revenue, current portion		1,700
Prepaid royalties		5,000
Deferred revenue, long-term portion		1,500
Foundation Medicine ("FMI") | Oncology assay interpretation services
Revenue recognized		1,000	400	400
Revenue, remaining performance obligation		5,000
Foundation Medicine ("FMI") | Oncology products
Revenue recognized		200	$ 3,500	$ 8,000
Revenue, remaining performance obligation		$ 19,300